iLite VEGF Assay Ready Cells
iLite VEGF Assay Ready Cells Developed and Manufactured by Svar Life Science
The Eagle Biosciences iLite VEGF Assay Ready Cells are intended for testing:
- VEGF activity
- NAb against VEGF activity
- Functional VEGF activity
Content: 250 µL of Assay Ready Cells suspended in DMEM medium with 20% heat inactivated fetal bovine serum (FBS) and 10% dimethyl sulfoxide (DMSO).
Storage: -80°C, Cells should be used within 30 min of thawing.
For Research Use Only
Key benefits of iLite Assays
- Highly specific reporter gene cell lines
- Very sensitive cell line responses (10 fold inductions)
- Assay Ready Cells – ready-to-use from the freezer, without culturing of cells
- Assays within a workday (typically 4-7 hour assays)
- Normalization gene, which eliminates unwanted matrix effects
Vascular Endothelial Growth Factor (VEGF) plays a critical role in both normal vascular growth and pathological angiogenesis and the humanized anti-VEGF antibody bevacizumab (Avastin(TM), Genentech) is used widely as a first-line therapy for colorectal cancer and other neoplastic diseases. Current methods for quantifying the activity of human VEGF, or antibodies that neutralize its activity, are bioassays based on the ability of anti-VEGF antibodies to inhibit the proliferation or migration of primary human umbilical vein endothelial cells (HUVEC) or other cells expressing VEGR receptors, following treatment of the cells with VEGF. Such assays can take several days to perform, are subject to a high degree of variation, and are difficult to validate. Reporter-gene assays based on the establishment of a stable cell line transfected with a luciferase reporter-gene placed under the control of a drug responsive chimeric promoter, provide highly sensitive and reproducible methods for quantifying drug activity.
iLite VEGF ARCs is a human embryonic kidney cell line (HEK-293*; ATCC #CRL-1573) that have been genetically engineered and optimized to respond to VEGF with specific, proportional expression of Firefly Luciferase. Normalization of cell counts and serum matrix effects is obtained by a second reporter gene, a NanoLuc Luciferase reporter gene construct, under control of a constitutive promotor.
* The HEK-293 cell line has been used under a license obtained from AdVec Inc.